Recursion Pharmaceuticals
RXRX
322 hedge funds and large institutions have $1.58B invested in Recursion Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 131 increasing their positions, 76 reducing their positions, and 51 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 76
70% more call options, than puts
Call options by funds: $52.4M | Put options by funds: $30.7M
1% more capital invested
Capital invested by funds: $1.57B → $1.58B (+$12.1M)
1.76% less ownership
Funds ownership: 77.63% → 75.87% (-1.8%)
3% less funds holding
Funds holding: 332 → 322 (-10)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
12% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$37.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.5M |
| 3 |
BlackRock
New York
|
+$17.7M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.5M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.4M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$9.11M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.6M |
| 4 |
VAS
Vestmark Advisory Solutions
Wakefield,
Massachusetts
|
-$3.77M |
| 5 |
Millennium Management
New York
|
-$3.74M |
RXRX Hedge Fund Activity: Q3 2025 in Review
322 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2025, worth a combined $1.58B — up 0.77% from $1.57B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of RXRX and 45 opened new positions — a net loss of 6 holders — while 76 trimmed existing stakes and 131 added.
The largest buyer was State Street, adding an estimated $37.2M. The largest seller was Fidelity Investments, cutting an estimated $12.4M.
- 322 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2025, down from 332 in Q2 2025.
- Funds reported $1.58B of Recursion Pharmaceuticals stock for Q3 2025, up 0.77% quarter-over-quarter.
- 45 funds opened new Recursion Pharmaceuticals positions in Q3 2025 and 51 closed out, a net change of -6 holders.
- The largest Recursion Pharmaceuticals buyer in Q3 2025 was State Street, an estimated $37.2M added.
- The largest Recursion Pharmaceuticals seller in Q3 2025 was Fidelity Investments, an estimated $12.4M sold.
Based on aggregated 13F filings for Q3 2025.